Oncolytics Biotech (ONCY) Receivables - Accured (2009)

Oncolytics Biotech's (ONCY) quarterly Receivables - Accured came in at $47573.0 in Q4 2009.

Oncolytics Biotech (ONCY) Receivables - Accured (2009) Analysis & Trends

Oncolytics Biotech (ONCY) has 1 years of Receivables - Accured data on file, last reported at $47573.0 in Q4 2009.

On a quarterly basis, Receivables - Accured changed N/A year-over-year to $47573.0 in Q4 2009; TTM through Dec 2009 was $47573.0, a N/A change from a year earlier, with the FY2009 full-year figure at $47573.0, changed N/A from the prior year.
Receivables - Accured for Q4 2009 stood at $47573.0.
Over the last five years, Receivables - Accured for ONCY reached as high as $47573.0 in Q4 2009 and fell as low as $47573.0 in Q4 2009.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Oncolytics Biotech	372.40 Mn	372.40 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2009	47,573.00
Dec 31, 2009	47,573.00